Generic medicine pricing is an area of national responsibility of European Union countries. This article aims to present the current status and impact of generic medicine pricing policies in ambulatory care in Europe. The study conducts a literature review of policies relating to free-pricing systems, price-regulated systems, price differentiation, price competition and discounts, and tendering procedures; and a survey of European generic medicine pricing policies. Competition from Indian generic medicine manufacturers, European variation in generic medicine prices and competition between generic medicine manufacturers by discount suggest that the potential savings to health care payers and patients from generic medicines are not fully realized in Europe. One way of attaining these savings may be to move away from competition by discount to competition by price. Free-pricing systems may drive medicine prices downwards under specific conditions. In price-regulated systems, regulation may lower prices of originator and generic medicines, but may also remove incentives for additional price reductions beyond those imposed by regulation. To date, little is known about the current status and impact of tendering procedures for medicines in ambulatory care. In conclusion, the European experience suggests that there is not a single approach towards developing generic medicine pricing policies in Europe.
References
[1]
Grootendorst, P.; Pierard, E.; Shim, M. Life-expectancy gains from pharmaceutical drugs: A critical appraisal of the literature. Expert Rev. Pharmacoecon. Outcomes Res.？2009, 9, 353–364.
[2]
Organisation for Economic Co-operation and Development. Health at a glance 2007; Organisation for Economic Co-operation and Development: Paris, France, 2007.
[3]
Crown, W.H.; Ling, D.; Berndt, E. Measuring the costs and benefits of pharmaceutical expenditures. Expert Rev. Pharmacoecon. Outcomes Res.？2002, 2, 467–475.
[4]
Simoens, S.; De Coster, S. Sustaining generic medicines markets in Europe. Leuven: Katholieke Universiteit Leuven. 2006. Available online: www.egagenerics.com , accessed on 4 December 2009.
[5]
Kanavos, P. Do generics offer significant savings to the UK National Health Service? Curr. Med. Res. Opin.？2007, 23, 105–116, doi:10.1185/030079907X159506. 17257472
Espin, J.; Rovira, J. Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe; DG Enterprise and Industry of the European Commission: Brussels, Belgium, 2007. Available online: http://ec.europa.eu/enterprise , accessed on 4 December 2009.
[8]
Simoens, S. Generic medicine pricing in Europe: Current issues and future perspective. J. Med. Econ.？2008, 11, 171–175.
[9]
European Generic Medicines Association. 2008 Market Review; European Generic Medicines Association: Brussels, Belgium, 2008.
[10]
Simoens, S. International comparison of generic medicine prices. Curr. Med. Res. Opin.？2007, 23, 2647–2654.
[11]
Magazzini, L.; Pammolli, F.; Riccaboni, M. Dynamic competition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur. J. Health Econom.？2004, 5, 175–182.
[12]
Martikainen, J.; Kivi, I.; Linnosmaa, I. European prices of newly launched reimbursable pharmaceuticals – a pilot study. Health Pol.？2005, 74, 235–246.
[13]
Schulz, A. Evolving dynamics of US and European generics markets. J. Generic Med.？2004, 2, 23–32.
[14]
Danzon, P.M.; Chao, L.W. Cross-national price differences for pharmaceuticals: How large, and why? J. Health Econ.？2000, 19, 159–195, doi:10.1016/S0167-6296(99)00039-9. 10947575
[15]
Garattini, L.; Tediosi, F. A comparative analysis of generics markets in five European countries. Health Pol.？2000, 51, 149–162.
[16]
De Joncheere, K.; Rietveld, A.H.; Huttin, C. Experiences with generics. Int. J. Risk Safety Med.？2002, 15, 101–109.
[17]
Brekke, K.R.; Grasdal, A.L.; Holm？s, T.H. Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? Eur. Econ. Rev.？2009, 53, 170–185, doi:10.1016/j.euroecorev.2008.03.004.
[18]
Puig-Junoy, J. A review of the impact of European pharmaceutical price regulation on generic price competition. PharmacoEconomics. in press.？
[19]
Bergman, M.A.; Rudholm, N. The relative importance of actual and potential competition: Empirical evidence from the pharmaceuticals market. J. Ind. Econ.？2003, 51, 455–467.
[20]
Ghislandi, S.; Krulichova, I.; Garattini, L. Pharmaceutical policy in Italy: Towards a structural change? Health Pol.？2005, 72, 53–63, doi:10.1016/j.healthpol.2004.02.012.
[21]
Kanavos, P.; Taylor, D. Pharmacy discounts on generic medicines in France: Is there room for further efficiency savings? Curr. Med. Res. Opin.？2007, 23, 2467–2476, doi:10.1185/030079907X219571. 17764613
[22]
Leopold, C.; Habl, C.; Vogler, S. Tendering of Pharmaceuticals in EU Member States and EEA Countries. Results from the Country Survey; ？BIG Forschungs- und Planungsgesellschaft mbH: Vienna, Austria, 2008.
[23]
Arickx, F.; Bormans, V.; Leveque, F.; Mortier, M.; Soete, E.; Vanhaeren, E. Public Tendering for Off patent Medicines in Belgium—The Simvastatin Case; RIZIV: Brussels, Belgium, 2009.
[24]
Price Waterhouse Coopers. Ontario Public Drug Programs Competitive Agreement Initiative.; Price Waterhouse Coopers: Ottawa, ON, Canada, 2007.
